Better Blood Pressure Control Could Prevent 518,476 Deaths a Year Across 20 Countries

A large mortality gap behind a familiar treatment

Improving blood pressure control to reach approximately 80% of eligible patients could prevent an estimated 518,476 cardiovascular deaths each year across 20 countries, according to preliminary research described in an American Heart Association release dated October 11, 2026. Only about 20% of adults with hypertension in those countries currently have their blood pressure controlled.

The analysis compared six preventive services and found the largest potential reduction in deaths from better hypertension management. Expanding appropriate statin treatment could prevent an estimated 340,682 annual cardiovascular deaths, while better glucose control in people with type 1 or type 2 diabetes could prevent 309,520. Increasing colon cancer screening could prevent another 206,767 deaths from that cancer each year.

These are modeled estimates, not deaths already prevented through a treatment program. They describe what might happen if countries substantially increased access to established preventive care and the proportion of patients meeting treatment targets. The findings come from a conference abstract that has not undergone peer review.

The American Heart Association's research release identifies Scott Pilla, an associate professor of medicine at Johns Hopkins University School of Medicine in Baltimore, as the researcher describing the results. The work was scheduled for the association's Hypertension Scientific Sessions in Arlington, Virginia.

What the researchers compared

The researchers selected 20 countries with the highest numbers of deaths from noncommunicable diseases, meaning diseases that are not transmitted between people. They modeled the populations eligible for six services: blood pressure control, statins when indicated, glucose control in people with diabetes, and screening for colon, breast and cervical cancers.

Age and sex specific estimates of eligibility and service use came from the Global Burden of Disease network, the NCD Risk Factor Collaboration, the World Health Organization's STEPwise surveillance program and its cancer screening databases. The researchers then estimated deaths potentially prevented if care reached approximately 80% of eligible patients, a benchmark drawn from leading U.S. health systems.

Eligibility mattered to the calculation. The model did not assume that everyone should receive a statin or undergo every cancer screening test. It applied clinical guideline criteria to identify patients for treatment and appropriate ages and intervals for screening.

The distinction between receiving care and achieving control also matters. A patient can have a hypertension diagnosis and take medication without reaching the blood pressure threshold. For blood pressure and diabetes, the modeled goal concerned successful control, rather than simply a prescription or a medical visit.

How far current care falls short

The baseline figures show the scale of the proposed expansion. Approximately one in five adults with hypertension had blood pressure below 140/90 mm Hg. Statin use among people with high cholesterol was 16%, and routinely indicated cancer screening ranged from 14% to 26%.

The release also gives a figure of 39% for people with type 1 or type 2 diabetes whose blood sugar was below the specified threshold. Its phrase "below optimal levels" is awkward, but the methods identify the glucose control target as hemoglobin A1c below 7.0%. The figure should not be interpreted as the proportion experiencing dangerously low blood sugar.

Moving blood pressure control from approximately 20% to 80% represents a rise of 60 percentage points, or four times the current proportion. Moving statin use from 16% to 80% would mean a rise of 64 percentage points and five times the current proportion. These comparisons show how ambitious the scenario is, even though it uses established treatments.

Pilla, the Johns Hopkins associate professor, described the gaps in preventive care and the opportunities in countries with lower middle incomes:

While there were substantial gaps in the use of preventive healthcare services for these conditions in all countries, lower-middle-income countries had large opportunities for improvement, with low rates of hypertension control and high cholesterol management and minimal use of cancer screening tests.

Where the largest blood pressure gains were projected

The model estimated that better blood pressure control could prevent 223,282 annual deaths in countries classified as having upper middle incomes and 223,655 in countries with lower middle incomes. The two estimates differ by just 373 deaths.

Together, those groups account for 446,937 of the 518,476 projected deaths prevented through hypertension control, or approximately 86.2%. That concentration is one of the strongest findings: most of the modeled benefit falls within the two middle income categories.

The release says outcomes were grouped using World Bank income classifications and that no low income countries were included. Although some descriptions call the entire sample a group of middle income countries, the release does not provide a complete country list or explain how the remaining 71,539 projected deaths were distributed. The figures therefore support the stated middle income comparisons, but not a detailed country ranking.

Selection by the absolute number of deaths also affects interpretation. The study focused on countries with a large mortality burden, not necessarily those with the highest individual risk or the weakest health services. Its results cannot automatically be extended to every country, particularly those outside the analysis.

Why the blood pressure threshold matters

The analysis counted hypertension as controlled when blood pressure was below 140/90 mm Hg. That differs from the treatment goal below 130/80 mm Hg in the American Heart Association's 2025 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults.

Blood pressure readings contain two numbers. The first measures pressure when the heart contracts, and the second measures pressure between beats. The unit mm Hg means millimeters of mercury. Someone below 140/90 could count as controlled in this model while still being above the association's treatment goal.

The estimated 518,476 deaths therefore should not be described as the result of bringing 80% of patients below 130/80. The model used the less demanding threshold. The release does not give a separate mortality estimate for achieving the lower target.

Daniel W. Jones, chair of the association's 2025 guideline writing committee, commented on the results but was not involved in the study. He is also dean and professor emeritus of the University of Mississippi School of Medicine. He described the value of reaching a treatment goal:

Treatment of high blood pressure to goal leads to longer lives and also healthier lives. This study should inspire clinicians and patients to give more attention to appropriate management of high blood pressure using both lifestyle measures and medication.

Statins and diabetes care also showed substantial benefits

Statin treatment ranked second among the preventive services, with an estimated 340,682 cardiovascular deaths prevented annually. Statins lower cholesterol, helping reduce the risk of cardiovascular events in patients for whom treatment is recommended. The study used eligibility criteria from the American Heart Association and American College of Cardiology's 2026 dyslipidemia guideline. Dyslipidemia means abnormal levels of cholesterol or other fats in the blood.

Glucose control ranked third, with 309,520 annual cardiovascular deaths potentially prevented among people with type 1 or type 2 diabetes. The model used an American Diabetes Association target of hemoglobin A1c below 7.0%. A1c measures the proportion of hemoglobin with glucose attached and reflects average blood sugar over roughly the previous two to three months.

These results show that the modeled opportunity extends beyond hypertension. Blood pressure control nevertheless produced the largest individual estimate, exceeding the statin estimate by 177,794 deaths and the glucose control estimate by 208,956 deaths each year.

The estimates should not simply be added together and presented as a guaranteed combined benefit. Patients can have hypertension, high cholesterol and diabetes at the same time, and treatments may prevent overlapping outcomes. The release does not establish how those overlaps would affect the total if every service were expanded simultaneously.

Colon screening led the cancer prevention estimates

Increasing colon cancer screening to approximately 80% of eligible patients was projected to prevent 206,767 deaths from that cancer annually. It produced the largest mortality reduction among the three cancer screening services, followed by cervical screening and then breast screening.

The release does not provide separate death estimates for cervical and breast screening. Their ranking can be reported, but their contributions cannot be quantified from the published figures. The 14% to 26% baseline screening range also is not broken down by cancer type in the release.

The model followed age and sex appropriate screening intervals recommended by the U.S. Preventive Services Task Force. Its scenario therefore concerned recommended screening among eligible patients, rather than universal testing. The cancer deaths prevented are also a different outcome from the cardiovascular deaths estimated for blood pressure, statin and glucose interventions.

What is still uncertain, and what comes next

The study identifies the potential scale of benefit, but it does not set out a plan for reaching 80% coverage or control. It does not specify how countries would expand access, maintain treatment, increase screening participation or pay for the changes.

Some countries had limited data on preventive service use, creating uncertainty in the baseline estimates. The release does not give uncertainty ranges around the projected deaths prevented. The precision of a figure such as 518,476 should therefore not be mistaken for certainty about the eventual outcome.

The research also remains preliminary. The American Heart Association says abstracts at its scientific meetings are not peer reviewed and that findings should be considered preliminary until a full manuscript is published in a peer reviewed journal. Publication in a conference supplement is not the same as that full review.

The release gives the following presentation and publication schedule:

• October 7 to 11, 2026: Hypertension Scientific Sessions in Arlington, Virginia.
• October 11, 2026, at 10:15 a.m. Eastern Time: scheduled oral presentation of abstract number 89.
• November 17, 2026: scheduled appearance of conference abstracts in a supplement to the journal Hypertension.

No date is given for publication of a full manuscript. The researchers propose further work on practical ways to close the gaps between eligibility, access to care and successful treatment. Until then, the study offers a comparison of potential benefits, rather than evidence that a particular national program has delivered them.

Key Points

• Achieving blood pressure control in approximately 80% of eligible patients could prevent an estimated 518,476 cardiovascular deaths annually across 20 studied countries.
• Current hypertension control was approximately 20%, using a threshold below 140/90 mm Hg.
• Countries in the two middle income groups accounted for approximately 86.2% of the projected hypertension benefit.
• Statins, glucose control and colon cancer screening also produced large modeled reductions in deaths.
• The study's blood pressure threshold differs from the AHA treatment goal below 130/80 mm Hg.
• The findings are preliminary, exclude low income countries and do not provide a practical implementation plan.